Patricia da Silva Mattosinhos

Mrs. Patricia da Silva Mattosinhos

Universidade Federal de Viçosa, Viçosa, Brazil
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
PMPatricia da Silva Mattosinhos
Patricia da Silva Mattosinhos
MSMariáurea Matias Sarandy
Mariáurea Matias Sarandy
Romulo Dias NovaesRomulo Dias Novaes
Romulo Dias Novaes
Debora EspositoDebora Esposito
Debora Esposito
Reggiani Vilela GoncalvesReggiani Vilela Goncalves
Reggiani Vilela Goncalves
The Brassicaceae family constitutes some of the most well-studied natural products in the world, due to their anti-inflammatory, anti-oxidative, and pro-regenerative properties as well as their ubiquitous distribution across the world. To evaluate the potential efficacy of the Brassicaceae family in the treatment of inflammatory skin disorders and wounds, based on preclinical evidence from in vivo and in vitro studies. This systematic review was performed according to the PRISMA guidelines, using a structured search on the PubMed-Medline, Scopus, and Web of Science platforms. The studies included were those that used murine models and in vitro studies to investigate the effect of Brassicaceae on skin disorders. Bias analysis and methodological quality assessments were examined through SYRCLE’s RoB tool. Brassicaceae have shown positive impacts on inflammatory regulation of the skin, accelerating the wound healing process, and inhibiting the development of edema. The studies showed that the Brassicaceae family has antioxidant activity and effects on the modulation of cyclooxygenase 2 and the nuclear factor kappa β (NFκβ) pathway. The secondary metabolites present in Brassicas are polyphenols (68.75%; n = 11), terpenes/carotenoids (31.25%; n = 5), and glycosylates (25%; n = 4), which are responsible for their anti-inflammatory, healing, and antioxidant effects. In addition, the current evidence is reliable because the bias analysis showed a low risk of bias. Our review indicates that compounds derived from Brassicaceae present exceptional potential to treat inflammatory skin diseases and accelerate cutaneous wound healing. We hope that our critical analysis can help to expedite clinical research and to reduce methodological bias, thereby improving the quality of evidence in future research. The registration number on the Prospero platform is CRD42021262953.

20 May 2025 in Molecules
Verified
Journal Article
Open access
PDF file
SPSilvania Pelinsari
Silvania Pelinsari
PMPatricia da Silva Mattosinhos
Patricia da Silva Mattosinhos
MDManoela Maciel dos Santos Dias
Manoela Maciel dos Santos Dias
RPRosinéa Aparecida de Paula
Rosinéa Aparecida de Paula
Romulo Dias NovaesRomulo Dias Novaes
Romulo Dias Novaes
Reggiani Vilela GoncalvesReggiani Vilela Goncalves
Reggiani Vilela Goncalves
(1) Background: This study evaluated the potential of a synthetic peptide (SGHPGAMGPVGPR), identified in the bullfrog (Lithobates catesbeianus) skin, in regulating inflammation and oxidative stress using RAW 264.7 macrophages; (2) Methods: Molecular docking determined its optimal interaction with cyclooxygenase (COX-2) an enzyme related to the production of prostaglandins, which play a crucial essential role in the inflammatory response. The peptide was commercially synthesized company, and its antioxidant capacity was assessed using DPPH and FRAP assays. Cell viability, nitric oxide (NO) levels, catalase (CAT), superoxide dismutase (SOD) and glutathione s-transferase (GST) activity, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) gene expression and cell production were additionally quantified. (3) Results: The peptide SGHPGAMGPVGPR, designated as P1, exhibited remarkable free radical scavenging capacity, antioxidant, and anti-inflammatory activities. No significant difference was observed in SOD and CAT activity in P1-treated macrophages, likely due to downregulation in the Nrf2/HO-1 pathway. Reduced GST activity was observed in these cells, which was potentially associated with TNF-α downregulation; (4) Conclusions: These findings suggest that P1 modulates the antioxidant response through pathways independent of classical antioxidant enzymes. Furthermore, decreased IL-6, COX2, and nuclear factor kappa B (NF-κB) expression was observed, indicating the involvement of a key pathway in the regulation of the OxInflammation process.

31 August 2026 in Purinergic Signalling
Verified
Journal Article
Open access
PDF file
SPSilvania Pelinsari
Silvania Pelinsari
Reggiani Vilela GoncalvesReggiani Vilela Goncalves
Reggiani Vilela Goncalves
PMPatricia da Silva Mattosinhos
Patricia da Silva Mattosinhos
Mariaurea Matias SarandyMariaurea Matias Sarandy
Mariaurea Matias Sarandy
EVEmerson Ferreira Vilela
Emerson Ferreira Vilela
Romulo Dias NovaesRomulo Dias Novaes
Romulo Dias Novaes
Purinergic signalling plays a central regulatory role on cell proliferation, migration, differentiation, survival, and inflammation. However, the impact of purinergic modulators-based therapies on tissue repair is still overlooked. By using a systematic review framework, we investigated the therapeutic relevance of purinergic agonists and antagonists in animal models of skin wound healing. Following PRISMA guidelines, PubMed/Medline, Scopus, Web of Science, Embase, and CINAHL databases were searched, identifying 12 in vivo preclinical studies. Risk of bias was assessed using the SYRCLE tool. Topical or oral administration of CGS-21680 (4-[{ N -ethyl-5 ’ -carbamoyladenos-2-yl}aminoethyl] phenylpropionic acid), UTP (Uridine-5'-triphosphate), NECA (5'-N-ethylcarboxamidoadenosine), ATP (adenosine triphosphate), PDRN (polydeoxyribonucleotide), ADP (Adenosine-5'-diphosphate) and TMPS (Thymidine 5'-O-monophosphorothioate) agonists stimulated wound contraction, fibroblast and keratinocyte proliferation, angiogenesis, and collagen biosynthesis. These effects were associated with activation of Nrf2 (Nuclear factor erythroid 2–related factor 2), MAPK (Mitogen-Activated Protein Kinase), and ERK/CREB pathways, inflammation and oxidative/nitrosative stress down-regulation, and increased anti-inflammatory/regulatory cytokines (IL-10, IL-13, TGF-β) and growth factors (FGF, EGF). Conversely, the purinergic antagonists DMPX (3,7-dimethyl-1-propargylxanthine), CSC (8-(3-chlorostyryl) caffeine), SUR (Suramin), ENP (enprofylline), caffeine, CLOP (clopidogrel), MRS 2179 (2′-deoxy-N6-methyladenosine-3′,5′-bisphosphate), and MRS 2395 (2-Chloro-3′,5′-O-(benzoyl-β,γ-methylene) adenosine 5′-triphosphate), as well as genetic knockout for purinergic receptors delayed wound closure by inhibiting these pathways, impairing angiogenesis, collagenogenesis, and aggravating inflammation and oxidative damage. Purinergic agonists were associated with improved wound healing through inflammatory and oxidative modulation, enhanced angiogenesis, increased cell proliferation, and accelerated wound closure, whereas antagonists or genetic deficiency of purinergic receptors impaired tissue repair. This review was registered in the PROSPERO database (CRD420251010254). Graphical abstract Overview of the effects of purinergic signalling modulation on cutaneous wound healing in murine models. Purinergic receptor activation by agonists accelerates wound closure, enhances cell proliferation and angiogenesis, and attenuates oxidative stress and pro-inflammatory cytokine production through activation of the PKA/ERK/CREB pathway. Conversely, receptor inhibition by antagonists or genetic deletion (KO) disrupts downstream signalling, resulting in delayed wound healing and increased inflammatory and oxidative damage.